Replies to post #4274 on Pfizer Inc (PFE)

[DewDiligence]

I absolutely think there is good money to be made in COVID antivirals. I have a large position in ENTA, which has a SARS-CoV-2 protease inhibitor, EDP-235, in late preclinical development (#msg-165291436).

ENTA has considerable expertise in this area from its work developing the protease inhibitor in Mavyret, the HCV drug sold by ABBV.